No profile data available.
Travere Therapeutics, Inc. (TVTX) is a healthcare company in the urinary system treatment drugs industry, based in San Diego, United States, with about 497 full-time employees.
It reported revenue of $490.73 million for fiscal year 2025, up 110.5% from fiscal year 2024, and net income of -$25.55 million. Its market capitalization was $4.85 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Travere Therapeutics reported $490.73 million in revenue for fiscal year 2025, up 110.5% from $233.18 million in fiscal year 2024.
$4.85 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Vera Therapeutics, Inc. (VERA), ProKidney Corp. (PROK), Akebia Therapeutics, Inc. (AKBA), Jyong Biotech Ltd. (MENS).